Journey Medical
DERM
71 hedge funds and large institutions have $55.7M invested in Journey Medical in 2026 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 32 increasing their positions, 18 reducing their positions, and 17 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 18
3.42% more ownership
Funds ownership: 52.15% → 55.57% (+3.4%)
8% less funds holding
Funds holding: 77 → 71 (-6)
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
34% less capital invested
Capital invested by funds: $85M → $55.7M (-$29.3M)
80% less call options, than puts
Call options by funds: $26K | Put options by funds: $133K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$6.34M |
| 2 |
BlackRock
New York
|
+$1.96M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.16M |
| 4 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$1.12M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$776K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$2.67M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$2.31M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.9M |
| 4 |
LCM
Legato Capital Management
San Francisco,
California
|
-$861K |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
-$843K |
DERM Hedge Fund Activity: Q1 2026 in Review
71 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Journey Medical (DERM) for Q1 2026, worth a combined $55.7M — down 34% from $85M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of DERM and 12 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 32 added.
The largest buyer was Wasatch Advisors, adding an estimated $6.34M. The largest seller was Essex Investment Management, exiting entirely with an estimated $2.67M sold.
- 71 institutional investors held Journey Medical (DERM) as of Q1 2026, down from 77 in Q4 2025.
- Funds reported $55.7M of Journey Medical stock for Q1 2026, down 34% quarter-over-quarter.
- 12 funds opened new Journey Medical positions in Q1 2026 and 17 closed out, a net change of -5 holders.
- The largest Journey Medical buyer in Q1 2026 was Wasatch Advisors, an estimated $6.34M added.
- The largest Journey Medical seller in Q1 2026 was Essex Investment Management, an estimated $2.67M sold.
Based on aggregated 13F filings for Q1 2026.